OABIOmniAb Inc. Common Stock
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Why Eli Lilly (LLY) Stock Is Up Today Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiring rights to a preclinical Alzheimer's drug and entering a collaboration for an ion channel program. | SStockStory | |
 Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals Eli Lilly (NYSE: LLY) announced new global collaborations focused on ion channel drug discovery with OmniAb and a trial partnership with Amplia Therapeutics in KRAS G12C-mutant lung cancer. The OmniAb agreement centers on applying its ion channel platform to Eli Lilly's neuroscience research pipeline. The Amplia collaboration targets a clinical trial program that combines FAK and KRAS G12C-directed therapies for lung cancer patients. These deals expand Eli Lilly's external R&D partnerships... | ||
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook Licensing activity strengthens the biotech's balance sheet. | ||
Top Midday Gainers OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery progra | MMT Newswires | |
 OmniAb lifts 2026 cash outlook following licensing momentum OmniAb, Inc. (NASDAQ:OABI) has increased its financial guidance for 2026 after recent technology licensing and business development activity strengthened its expected year-end cash position. | ||
 OmniAb (OABI) Q2 2026 Earnings Call Transcript Clinical programs advance as OmniAb raises full-year revenue guidance to $32M-$36M. | ||
 OmniAb Q2 Earnings Call Highlights OmniAb (NASDAQ:OABI) reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook. Revenue for the second quarter totaled $13.4 million, compared with $3.9 million | ||
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... OmniAb raises full-year guidance to $32M-$36M, driven by milestone achievements and growing partner momentum. | ||
 OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +54.55% and +149.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
EExec Edge | ||
IInsider Monkey | ||